Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monotherapy of an NMDA Enhancer for Schizophrenia
NCT04745143Phase 2Recruiting
- Sponsor
- China Medical University Hospital
- Start
- Jan 2018
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sodium benzoate in schizophrenia, sponsored by China Medical University Hospital. Started Jan 2018; status: recruiting.
02
Drugs
sodium benzoate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04745143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04745143.